These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27159879)

  • 21. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN.
    Qiu Y; Guo L; Zhang S; Xu B; Gao Y; Hu Y; Hou J; Bai B; Shen H; Mao P
    Drug Deliv; 2016 Sep; 23(7):2391-2398. PubMed ID: 25625495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of adjuvant formulations and delivery systems.
    García A; De Sanctis JB
    APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.
    van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K
    Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microneedles for vaccine delivery: challenges and future perspectives.
    Shin CI; Jeong SD; Rejinold NS; Kim YC
    Ther Deliv; 2017 Jun; 8(6):447-460. PubMed ID: 28530151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances and Potential Applications of Chitosan Nanoparticles as a Delivery Carrier for the Mucosal Immunity of Vaccine.
    Li D; Fu D; Kang H; Rong G; Jin Z; Wang X; Zhao K
    Curr Drug Deliv; 2017; 14(1):27-35. PubMed ID: 27494157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanocarriers for systemic and mucosal vaccine delivery.
    Shahiwala A; Vyas TK; Amiji MM
    Recent Pat Drug Deliv Formul; 2007; 1(1):1-9. PubMed ID: 19075870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational application of nanoadjuvant for mucosal vaccine delivery system.
    Dewangan HK
    J Immunol Methods; 2020; 481-482():112791. PubMed ID: 32387695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal adjuvants: Opportunities and challenges.
    Zeng L
    Hum Vaccin Immunother; 2016 Sep; 12(9):2456-8. PubMed ID: 27159278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection.
    Hickey DK; Aldwell FE; Tan ZY; Bao S; Beagley KW
    Vaccine; 2009 Nov; 27(50):6983-90. PubMed ID: 19800441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissolving Microneedle Arrays for Transdermal Delivery of Amphiphilic Vaccines.
    An M; Liu H
    Small; 2017 Jul; 13(26):. PubMed ID: 28544329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Needle-free vaccine delivery.
    Giudice EL; Campbell JD
    Adv Drug Deliv Rev; 2006 Apr; 58(1):68-89. PubMed ID: 16564111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioadhesive delivery systems for mucosal vaccine delivery.
    Baudner BC; O'Hagan DT
    J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
    Bal SM; Ding Z; van Riet E; Jiskoot W; Bouwstra JA
    J Control Release; 2010 Dec; 148(3):266-82. PubMed ID: 20869998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing efficacy of mucosal vaccines.
    Gebril A; Alsaadi M; Acevedo R; Mullen AB; Ferro VA
    Expert Rev Vaccines; 2012 Sep; 11(9):1139-55. PubMed ID: 23151169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Archaeal lipid mucosal vaccine adjuvant and delivery system.
    Patel GB; Chen W
    Expert Rev Vaccines; 2010 Apr; 9(4):431-40. PubMed ID: 20370552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using procedure of emulsification-lyophilization to form lipid A-incorporating cochleates as an effective oral mucosal vaccine adjuvant-delivery system (VADS).
    Wang N; Wang T; Zhang M; Chen R; Deng Y
    Int J Pharm; 2014 Jul; 468(1-2):39-49. PubMed ID: 24704308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery.
    Pielenhofer J; Sohl J; Windbergs M; Langguth P; Radsak MP
    Front Immunol; 2020; 11():266. PubMed ID: 32174915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.
    Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD
    Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
    Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
    Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.